BACKGROUND: Blood group O individuals are known to have larger amounts of anti-ABO blood group (anti-A/B) IgG antibodies than A or B individuals. Therefore, in ABO-incompatible (ABOI) kidney transplantation (KTX), it is expected that blood group O recipients are more likely to suffer graft damage, because anti-A/B IgG antibodies are believed to be responsible for worse graft outcomes. METHODS: This study assessed the graft outcomes between blood group O and non-O recipients in ABOI-KTX. A total of 164 consecutive recipients who underwent ABOI-KTX between 1990 and 2007 under three different immunosuppressive protocols were enrolled in this study. The study population was divided into two groups: (i) recipients with blood group O (n=87) and (ii) recipients with blood group A or B (non-O) (n=77). RESULTS: High anti-A/B IgG titers were predominant in the O group (P<0.001), whereas no significant difference was observed in the IgM titers. The overall graft survival rate did not differ between the two groups; however, the 6-month graft survival rate was significantly lower in the O group (86% vs. 97%, P=0.011). Among 14 recipients who suffered graft loss within 6 months after transplantation, 12 (86%) were O recipients. The cumulative incidence of acute antibody-mediated rejection was significantly higher in the O group (60 days, 31 vs. 14%, P=0.013). CONCLUSION: Our results may indicate that being a blood group O recipient is at great risk for experiencing early allograft deterioration, probably caused by anti-A/B IgG antibodies in ABOI-KTX.
BACKGROUND: Blood group O individuals are known to have larger amounts of anti-ABO blood group (anti-A/B) IgG antibodies than A or B individuals. Therefore, in ABO-incompatible (ABOI) kidney transplantation (KTX), it is expected that blood group O recipients are more likely to suffer graft damage, because anti-A/B IgG antibodies are believed to be responsible for worse graft outcomes. METHODS: This study assessed the graft outcomes between blood group O and non-O recipients in ABOI-KTX. A total of 164 consecutive recipients who underwent ABOI-KTX between 1990 and 2007 under three different immunosuppressive protocols were enrolled in this study. The study population was divided into two groups: (i) recipients with blood group O (n=87) and (ii) recipients with blood group A or B (non-O) (n=77). RESULTS: High anti-A/B IgG titers were predominant in the O group (P<0.001), whereas no significant difference was observed in the IgM titers. The overall graft survival rate did not differ between the two groups; however, the 6-month graft survival rate was significantly lower in the O group (86% vs. 97%, P=0.011). Among 14 recipients who suffered graft loss within 6 months after transplantation, 12 (86%) were O recipients. The cumulative incidence of acute antibody-mediated rejection was significantly higher in the O group (60 days, 31 vs. 14%, P=0.013). CONCLUSION: Our results may indicate that being a blood group O recipient is at great risk for experiencing early allograft deterioration, probably caused by anti-A/B IgG antibodies in ABOI-KTX.
Authors: Christina Melexopoulou; Smaragdi Marinaki; George Liapis; Chrysanthi Skalioti; Maria Gavalaki; George Zavos; John N Boletis Journal: World J Transplant Date: 2015-12-24
Authors: John R Montgomery; Jonathan C Berger; Daniel S Warren; Nathan T James; Robert A Montgomery; Dorry L Segev Journal: Transplantation Date: 2012-03-27 Impact factor: 4.939
Authors: Eun Su Park; Kyung Il Jo; Jeong Won Shin; Rojin Park; Tae Yoon Choi; Hae In Bang; Gum Ran Chai; Soon Gyu Yun Journal: Ann Lab Med Date: 2014-04-08 Impact factor: 3.464
Authors: Madelon van Agteren; Willem Weimar; Annelies E de Weerd; Peter A W Te Boekhorst; Jan N M Ijzermans; Jaqueline van de Wetering; Michiel G H Betjes Journal: J Transplant Date: 2014-02-06
Authors: Guido Moll; Annika Hult; Lena von Bahr; Jessica J Alm; Nina Heldring; Osama A Hamad; Lillemor Stenbeck-Funke; Stella Larsson; Yuji Teramura; Helene Roelofs; Bo Nilsson; Willem E Fibbe; Martin L Olsson; Katarina Le Blanc Journal: PLoS One Date: 2014-01-13 Impact factor: 3.240
Authors: Annelies de Weerd; Alieke Vonk; Hans van der Hoek; Marian van Groningen; Willem Weimar; Michiel Betjes; Madelon van Agteren Journal: BMC Nephrol Date: 2014-02-12 Impact factor: 2.388